Jpmorgan Chase & CO Arcellx, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Arcellx, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 683,581 shares of ACLX stock, worth $58.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
683,581
Previous 224,456 204.55%
Holding current value
$58.2 Million
Previous $17.1 Million 162.33%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$60.26 - $79.13 $27.7 Million - $36.3 Million
459,125 Added 204.55%
683,581 $44.8 Million
Q4 2024

Feb 12, 2025
SELL
$75.39 - $106.53 $1.94 Million - $2.73 Million
-25,667 Reduced 10.26%
224,456 $17.1 Million
Q3 2024

Dec 26, 2024
SELL
$50.91 - $86.61 $572,024 - $973,149
-11,236 Reduced 4.3%
250,123 $20.9 Million
Q3 2024

Nov 08, 2024
SELL
$50.91 - $86.61 $572,024 - $973,149
-11,236 Reduced 4.3%
250,123 $20.9 Million
Q2 2024

Dec 26, 2024
BUY
$49.74 - $66.98 $558,878 - $752,587
11,236 Added 4.49%
261,359 $14.4 Million
Q2 2024

Aug 12, 2024
SELL
$49.74 - $66.98 $14.4 Million - $19.5 Million
-290,391 Reduced 52.63%
261,359 $14.4 Million
Q1 2024

Dec 26, 2024
BUY
$51.85 - $73.49 $15.6 Million - $22.2 Million
301,627 Added 120.59%
551,750 $38.4 Million
Q1 2024

May 10, 2024
SELL
$51.85 - $73.49 $2.6 Million - $3.69 Million
-50,163 Reduced 8.33%
551,750 $38.4 Million
Q4 2023

Dec 26, 2024
BUY
$31.75 - $57.99 $11.2 Million - $20.4 Million
351,790 Added 140.65%
601,913 $33.4 Million
Q4 2023

Feb 12, 2024
BUY
$31.75 - $57.99 $1.21 Million - $2.2 Million
38,014 Added 6.74%
601,913 $33.4 Million
Q3 2023

Nov 14, 2023
BUY
$31.51 - $37.4 $7.45 Million - $8.84 Million
236,461 Added 72.22%
563,899 $20.2 Million
Q2 2023

Aug 11, 2023
SELL
$27.49 - $46.9 $6.1 Million - $10.4 Million
-221,759 Reduced 40.38%
327,438 $10.4 Million
Q1 2023

May 18, 2023
BUY
$26.92 - $33.94 $968,312 - $1.22 Million
35,970 Added 7.01%
549,197 $16.9 Million
Q1 2023

May 11, 2023
SELL
$26.92 - $33.94 $6.21 Million - $7.83 Million
-230,771 Reduced 31.02%
513,227 $15.8 Million
Q4 2022

Feb 13, 2023
BUY
$17.18 - $33.0 $10.2 Million - $19.5 Million
590,980 Added 386.22%
743,998 $23 Million
Q3 2022

Nov 14, 2022
BUY
$16.67 - $22.04 $473,628 - $626,200
28,412 Added 22.8%
153,018 $2.87 Million
Q2 2022

Aug 11, 2022
BUY
$7.21 - $24.43 $867,651 - $2.94 Million
120,340 Added 2820.91%
124,606 $2.25 Million
Q1 2022

May 11, 2022
BUY
$12.97 - $19.14 $55,330 - $81,651
4,266 New
4,266 $60,000

Others Institutions Holding ACLX

# of Institutions
219
Shares Held
49.1M
Call Options Held
245K
Put Options Held
885K
View Full List

About Arcellx, Inc.

ACLX Quotes by TradingView
  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.73B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email